Company Overview and News
Ladies and gentlemen, thank you for standing by. Welcome to Bayer’s Investor and Analysts Conference Call on the Second Quarter 2018 Results. Throughout today's recorded presentation, all participants will be in a listen-only mode. The presentation will be followed by a question-and-answer session. [Operator Instructions]
MON MS OTCB
Perrigo Company plc (PRGO - Free Report) reported second-quarter 2018 adjusted earnings of $1.22 per share, which beat the Zacks Consensus Estimate of $1.21. Earnings growth was flat year over year.
SGEN VRTX PRGO UCTI OTCB UCTT
As the federal government sets aside money to look to the skies in the wake of the announcement of a national space agency, the case is already being put forward for WA to play a starring role in the organisation.
2018-05-21 proactiveinvestors.com.au - 2
Creso Pharma Ltd (ASX:CPH) has signed a deal to commercialise its CBD (cannabidiol) hemp-based nutraceutical product cannaQIX® in the Benelux region (Belgium, the Netherlands, and Luxembourg).
It’s official … almost. After years of lobbying and pleading, the gambling industry finally got the nod of approval for the United States’ highest level of justice. The Supreme Court decided on Monday that the federal ban on sports betting that’s been in place for more than a couple of decades is an unconstitutional measure.
MGM WIMHF SGMS WYNN CHDN IGT WMH WIMHY MSG CZR PENN TSG OTCB
2018-04-02 channelnewsasia - 1
Trading firms are negotiating buying, selling and lending digital currencies like bitcoin and ether over Skype, catering to big investors looking to avoid rocking already volatile online exchanges.
JBK GSC TFG GSJ GS GLSSP GJS OTCB
NEW YORK/LONDON (Reuters) - Trading firms are negotiating buying, selling and lending digital currencies like bitcoin and ether over Skype, catering to big investors looking to avoid rocking already volatile online exchanges.
JBK GSC TFG GSJ GS GLSSP GJS OTCB
Australian 3D printing company 3D Systems has helped Netherlands-based company Seatools to show off its custom designs at the Offshore Technology Conference (OTC) in Houston, Texas.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to EBR:OTCB / OTC on message board site Silicon Investor.